News Headlines Article

Gilead owes Merck $200M in damages over drug patents
Modern Healthcare

The federal jury in a high-stakes patent trial ordered drugmaker Gilead to pay rival Merck $200 million in damages for infringing on patents for hepatitis C drugs.

That’s far below the billions Merck sought, but the trial moves to a new phase next Wednesday, when the jury will decide whether Merck is due royalties on sales of Gilead’s blockbuster hepatitis C drugs, Harvoni and Sovaldi.

The jury in San Jose, California, on Tuesday upheld the validity of two patents Merck and partner Ionis Pharmaceuticals filed in 2002.